Posted in | News | Nanobusiness

Cambrios Technologies Raises $14.5 Million in Series D Financing Round

Cambrios Technologies Corporation, an electronic materials company commercializing ClearOhm™ coating material for producing transparent conductive films, announced today that the company has received investments totaling $14.5 million in a first closing of its Series D Financing Round.

All of the company’s existing institutional preferred shareholders participated in the round, including ARCH Venture Partners, Alloy Ventures, Oxford Bioscience Partners, Harris & Harris Group, Altitude Life Science Ventures, Presidio Ventures, Mitsubishi UFJ Capital, In-Q-Tel, Avalon Ventures, Lux Capital, Kidron LLC, Headland Ventures, and Alexandria Real Estate Equities.

In addition, three strategic partners made investments in the company. These include:

  • Sumitomo Corporation – one of Japan’s largest trading companies and Cambrios’ Japan and Taiwan distributor,
  • Chisso Corporation, which has a very large market share of liquid crystal material used to manufacture LCDs; Cambrios develops and commercializes products for LCD manufacturers exclusively with Chisso, and
  • Nissha Printing Co. Ltd. – the world’s largest manufacturer of touch screens; Cambrios has a development and sales agreement with Nissha involving rapid commercialization of ClearOhm™ coating material-based products for the touch screen industry.

“Our investors are strong believers in our progress and in our plan,” said Michael Knapp, Cambrios President & CEO. “We are very grateful to them for their continued support. In addition, we have an excellent relationship with our strategic partners and there is tremendous mutual commitment to achieving our collaborative business goals. The company is very lucky to have them as investors.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.